A Randomized Phase II Trial Comparing Capecitabine/CDDP(XP) and S-1/CDDP(SP) as the First-line Treatment for Advanced Gastric Cancer (XParTS II).
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Capecitabine; Cisplatin; Gimeracil/oteracil/tegafur
- Indications Gastric cancer
- Focus Biomarker; Therapeutic Use
- Acronyms XParTS II
- 27 Jul 2017 Biomarkers information updated
- 23 Sep 2013 Planned end date changed from 1 Jun 2014 to 1 Jun 2015 as reported by ClinicalTrials.gov.
- 23 Sep 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.